Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression.
|
| Abstract |
Broadly reactive neutralizing antibodies are the focus of human immunodeficiency virus (HIV) type 1 vaccine design. However, only little is known about their role in acquired immunodeficiency syndrome (AIDS) pathogenesis and the factors associated with their development. Here we used a multisubtype panel of 23 HIV-1 variants to determine the prevalence of cross-reactive neutralizing activity in serum samples obtained approximately 35 months after seroconversion from 82 HIV-1 subtype B-infected participants from the Amsterdam Cohort Studies on HIV Infection and AIDS. Of these patients, 33%, 48%, and 20%, respectively, had strong, moderate, or absent cross-reactive neutralizing activity in serum. Viral RNA load at set point and AIDS-free survival were similar for the 3 patient groups. However, higher cross-reactive neutralizing activity was significantly associated with lower CD4(+) T cell counts before and soon after infection. Our findings underscore the importance of vaccine-elicited immunity in protecting from infection. The association between CD4(+) T cell counts and neutralizing humoral immunity may provide new clues as to how to achieve this goal.
|
|---|---|
| Authors | Zelda Euler, Marit J van Gils, Evelien M Bunnik, Pham Phung, Becky Schweighardt, Terri Wrin, Hanneke Schuitemaker |
| Journal | The Journal of infectious diseases (J Infect Dis) Vol. 201 Issue 7 Pg. 1045-53 (Apr 01 2010) ISSN: 1537-6613 [Electronic] United States |
| PMID | 20170371 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't) |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!